European Respiratory Journal

Papers
(The H4-Index of European Respiratory Journal is 61. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
The right ventricle tamed1024
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis751
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?633
Similarity network fusion for the integration of multi-omics and microbiomes in respiratory disease371
Chymase-1: a “MAST”-er switch in COPD?332
Salivary polyreactive antibodies andHaemophilus influenzaeare associated with respiratory infection severity in young children with recurrent respiratory infections233
The Cochrane review of electronic cigarettes for smoking cessation: remaining focused on the evidence205
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease195
Missing airways, ventilation defects and conductive airway physiology in asthma166
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe157
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow144
A breath of the future: a novel human model for COPD and beyond141
The lung that rules the heart140
Randomised controlled trials utilisingFENOto manage asthma: is it time to acknowledge that “one size does not fit all”?127
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?123
Prenatal exposure to greenness and early childhood pneumonia: a nationwide study in Japan123
The NIVO score: can it help to improve noninvasive ventilation in daily clinical practice?117
“The Noninvasive Ventilation Outcomes (NIVO) score: prediction of in-hospital mortality in exacerbations of COPD requiring assisted ventilation.” Tom Hartley, Nicholas D. Lane, John Steer,et al115
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)114
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet111
Combining rituximab with mycophenolate for the treatment of interstitial lung disease110
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD106
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial102
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?93
Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume92
Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing ofM. tuberculosis91
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor90
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD89
A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis84
Antiviral CD8+T-cell immune responses are impaired by cigarette smoke and in COPD83
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey81
Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis81
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study80
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnoea80
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis80
Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry80
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation79
The environmental impact of inhaled therapy: making informed treatment choices78
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection77
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study76
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms76
Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era75
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target75
Genomic classifier for usual interstitial pneumonia combined with bronchoalveolar lavage cellular profile: potential use in the clinical management of new onset ILD?74
Treatment algorithm for pulmonary arterial hypertension74
The association between immunosuppressants and outcomes of COVID-1973
Impact of hepatopulmonary syndrome in liver transplantation candidates and the role of angiogenesis72
Associations of hiatus hernia with CT-based interstitial lung changes: the MESA Lung Study72
Prognostic phenotypes of early-stage lung adenocarcinoma72
Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination72
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?72
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?71
The limits of normal of pulmonary arterial wedge pressure71
Reply: Tuberculosis screening in migrants to the EU/EEA and UK71
Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients71
Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough70
Clean air for healthy lungs – an urgent call to action: European Respiratory Society position on the launch of the WHO 2021 Air Quality Guidelines69
Screening asymptomaticBMPR2mutation carriers: a new frontier for pulmonary hypertension physicians?69
Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis65
Pleural mesothelioma: surgery questioned again?64
Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?61
0.08233380317688